Aditya Bardia, MD, MPH, FASCO

home / authors / aditya-bardia-md-mph-fasco

Articles

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH, FASCO;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH, FASCO;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

Aditya Bardia, MD, MPH, FASCO;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
June 18th 2025
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH, FASCO;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

DESTINY-Breast06 Efficacy Surpasses SOC in HER2-Low/Ultralow Breast Cancer

DESTINY-Breast06 Efficacy Surpasses SOC in HER2-Low/Ultralow Breast Cancer

Aditya Bardia, MD, MPH, FASCO
February 13th 2025

Findings from DESTINY-Breast06 showed a PFS of 13.2 months for patients given T-DXd for HER2-low or ultralow breast cancer.

T-DXd Approval Appears Significant in HER2-Low/Ultralow Breast Cancer

T-DXd Approval Appears Significant in HER2-Low/Ultralow Breast Cancer

Aditya Bardia, MD, MPH, FASCO
February 12th 2025

Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.

Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.

T-DXd Benefit May Extend to Earlier Settings and HER2-Low Breast Cancers

Aditya Bardia, MD, MPH, FASCO
January 28th 2025

Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH, FASCO;Joyce O’Shaughnessy, MD;Francois Clement Bidard;Phillipe Aftimos;Javier Cortes;Janice Lu, MD, PhD ;Giulia Tonini;Kathy Puyana Theall;Alessandro Paoli;Virginia Kaklamani, MD, DSc
August 24th 2024
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

Fatima Cardoso;Joyce O’Shaughnessy, MD;Heather McArthur, MD, MPH;Peter Schmid, MD;Javier Cortés, MD;Nadia Harbeck, MD, PhD;Melinda L. Telli, MD;David W. Cescon;Peter A. Fasching;Zhimin Shao;Delphine Loirat;Yeon Hee Park;Manuel Gonzalez Fernandez;Gábor Rubovszky;Seock-Ah Im;Rina Hui;Toshimi Takano;Fabrice André;Hiroyuki Yasojima;Zhenzhen Liu;Yu Ding;Liyi Jia;Vassiliki Karantza;Konstantinos Tryfonidis;Aditya Bardia, MD, MPH, FASCO
August 18th 2024
12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

Javier Cortés, MD;François-Clément Bidard;Aditya Bardia, MD, MPH, FASCO;Virginia G. Kaklamani, MD, DSc;Ioanna Vlachaki;Giulia Tonini;Nassir Habboubi;Philippe Aftimos
August 17th 2024
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Gerald Batist;Javier Cortés, MD;Massimo Cristofanilli, MD;Giuseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Komal Jhaveri;Cynthia X. Ma, MD, PhD;Heather A. Parsons, MD, MPH;Hope S. Rugo, MD;Sarah L. Sammons;Daniel G. Stover;Chris Twelves, MD, FRCP;Aditya Bardia, MD, MPH, FASCO;Paul V. Plourde;David J. Portman;Senthil Damodaran
August 12th 2024
20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Sara M. Tolaney, MD, MPH;Aditya Bardia, MD, MPH, FASCO;Frederik Marmé;Javier Cortés, MD;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Oh Kyu Yoon;Hao Wang;Wendy Verret;Hope S. Rugo, MD
August 8th 2024
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, FACP;Daniil Stroyakovskiy;Denise A. Yardley, MD;Chiun-Sheng Huang;Peter A. Fasching;John Crown;Aditya Bardia, MD, MPH, FASCO;Stephen Chia;Seock-Ah Im;Miguel Martin, MD, PhD;Sherene Loi, MD, PhD;Binghe Xu;Sara A. Hurvitz, MD;Carlos Barrios;Michael Untch, MD, PhD;Rebecca Moroose;Frances Visco;Federico Parnizari;Farhat Ghaznawi;Zheng Li;Sorcha Waters;Arunava Chakravartty;Dennis J. Slamon, MD, PhD
August 7th 2024
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH, FASCO;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH, FASCO;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

Philippe Aftimos;Javier Cortes;Francois Clement Bidard;Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH, FASCO;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;Patrick Neven, MD, PhD
April 28th 2023
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Aditya Bardia, MD, MPH, FASCO;Francois Clement Bidard;Patrick Neven, MD, PhD;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Philippe Aftimos;Javier Cortes;Simona Scartoni;Nassir Habboubi;Virginia Kaklamani, MD, DSc
April 28th 2023
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

Aditya Bardia, MD, MPH, FASCO;Ian E. Krop;Funda Meric-Bernstam, MD;Anthony W. Tolcher;Toru Mukohara;Aaron Lisberg;Toshio Shimizu;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Takahiro Kogawa
April 28th 2023
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Aditya Bardia, MD, MPH, FASCO;Ian E. Krop;Dejan Juric;Takahiro Kogawa;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Toru Mukohara;Takuya Tsunoda;Senthil Damodaran;Funda Meric-Bernstam, MD
April 28th 2023
26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH, FASCO;Phillippe Aftimos;Javier Cortes;Patrick Neven, MD, PhD;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;François-Clément Bidard
April 27th 2023
28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

Kevin Kalinsky, MD, MS;Erika P. Hamilton, MD;Laura Spring;Peter A. Fasching;Sandra Franco, MD;Richard De Boer;Javier Cortes;Dejan Juric;Aditya Bardia, MD, MPH, FASCO;Sina Haftchenary;Agnes Lteif;Juan Pablo Zarate;Liyi Cen;Patrick Neven, MD, PhD
April 27th 2023
31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

Aditya Bardia, MD, MPH, FASCO;Lajos Pusztai, MD, DPhil;Kathy S. Albain, MD;Kevin Kalinsky, MD, MS;Dawn Herman;William Barlow;Claudine Isaacs, MD;Micah Maxwell;Nadia Harbeck, MD, PhD;Priyanka Sharma, MD
April 27th 2023
48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

Sara M. Tolaney, MD, MPH;Peter Schmid, MD;Javier Cortes;Frederik Marmé;Hope S. Rugo, MD;Mafalda Oliveira;Delphine Loirat;Komal Jhaveri;Oh Kyu Yoon;Monica Motwani;Hao Wang;Rosemary Delaney;Aditya Bardia, MD, MPH, FASCO
April 27th 2023
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH, FASCO;Frederik Marmé;Javier Cortes;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Hao Wang;Wendy Verret;Sara M. Tolaney, MD, MPH
April 27th 2023
55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH, FASCO;Javier Cortes;Giuseppe Curigliano;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sibylle Loibl;Simona Scartoni;Tarek Sahmoud, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Joyce A. O’Shaughnessy
April 27th 2023
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

Hope S. Rugo, MD;Joyce O'Shaughnessy, MD;Komal Jhaveri;Sara M. Tolaney, MD, MPH;Fatima Cardoso;Aditya Bardia, MD, MPH, FASCO;Purnima Pathak;Sina Haftchenary;Peter A. Fasching
April 26th 2023
Experts on breast cancer

Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care

Aditya Bardia, MD, MPH, FASCO;Alison Conlin, MD
December 5th 2022

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.

Expert on breast cancer

Interpreting Data From ASCENT: Practical Use of Sacituzumab Govitecan in mTNBC

Aditya Bardia, MD, MPH, FASCO;Alison Conlin, MD
December 5th 2022

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Expert on breast cancer

Sacituzumab Govitecan in mTNBC: Results From the ASCENT Study

Aditya Bardia, MD, MPH, FASCO;Alison Conlin, MD
November 30th 2022

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Experts on breast cancer

Metastatic Triple-Negative Breast Cancer: An Evolving Treatment Landscape

Aditya Bardia, MD, MPH, FASCO;Alison Conlin, MD
November 30th 2022

Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.

12>

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Clinical Implications Remain After Dasatinib CRL in CML/ALL
Published: October 28th 2025 | Updated: November 5th 2025
Clinical Implications Remain After Dasatinib CRL in CML/ALL